An update of the NeoFox study plan has begun as the previous observations have been confirmed and expanded in an updated analysis
The positive findings reported on August 16, 2022, have now been confirmed and expanded. WntResearch will thus revise the study plan for the ongoing NeoFox phase 2 study with Foxy-5 to more quickly generate the information required to take the drug candidate to the next step towards becoming a valuable tool in the treatment of cancer.WntResearch takes a very positive view of the statistically confirmed observations. After analyses of additional pathology reports from the NeoFox phase 2 study, reduced tumour burden (in primary tumour and regional lymph nodes), so-called down staging, as well